血清甲氨蝶呤水平在评估银屑病患者生物制剂药物依从性中的应用。
The use of serum methotrexate level as an assessment of biochemical drug adherence in psoriasis.
机构信息
Dermatology Centre, Northern Care Alliance NHS Foundation Trust, Manchester, UK.
NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.
出版信息
Br J Dermatol. 2024 May 17;190(6):927-929. doi: 10.1093/bjd/ljae096.
Psoriasis is a common inflammatory skin condition affecting approximately 2–3% of people worldwide. Methotrexate (MTX) is a cheap and effective drug that is often recommended as the first-choice systemic agent for psoriasis. Around 40–50% of patients achieve a good response; however, mechanisms of nonresponse are poorly understood. It is not known whether biochemical MTX adherence in patients with psoriasis is suboptimal and requires intervention. Our aim was to audit biochemical MTX adherence using a sensitive liquid chromatography–tandem mass spectrometry in patients prescribed oral MTX for the treatment of psoriasis at our tertiary dermatology centre. Ethical approval for this audit was not required as confirmed by the Health Research Authority.
银屑病是一种常见的炎症性皮肤病，影响全球约 2-3%的人群。甲氨蝶呤（MTX）是一种廉价且有效的药物，常被推荐为银屑病的首选全身药物。大约 40-50%的患者有良好的反应；然而，对无反应的机制了解甚少。目前尚不清楚银屑病患者的生物化学 MTX 依从性是否不理想，需要干预。我们的目的是使用敏感的液相色谱-串联质谱法在我们的三级皮肤科中心接受口服 MTX 治疗银屑病的患者中检测生物化学 MTX 依从性。该审计得到了健康研究管理局的确认，因此不需要伦理批准。
Zotero 插件